^
    Back
    Association details:
    Biomarker:KIT D816V
    Cancer:Chronic Myeloid Leukemia
    Drug:Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Leuk Res
    Title:

    Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia

    Published date:
    06/02/2023
    Excerpt:
    An 80 year old man initially presented for evaluation of aCML. A bone marrow biopsy was completed, and next generation sequencing was notable for a novel KIT D816V mutation. Patient was started on avapritinib leading to significant improvement in leukocytosis and extinction of the D816V mutation over 17 months of treatment.
    DOI:
    10.1016/j.lrr.2023.100371